On the public citation graph

Effective Treatment of Rheumatoid Arthritis-Associated Interstitial Lung Disease by B-Cell Targeted Therapy with Rituximab

0 signed · 25 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1080/03009740410005845openalex-snapshot
Death rates and causes of death in patients with rheumatoid arthritis: a population‐based study
inferredcites →https://doi.org/10.1093/rheumatology/41.3.262openalex-snapshot
Investigation of the chronic pulmonary effects of low-dose oral methotrexate in patients with rheumatoid arthritis: a prospective study incorporating HRCT scanning and pulmonary function tests
inferredcites →https://doi.org/10.1378/chest.125.6.2169openalex-snapshot
Combined Corticosteroid and Cyclophosphamide Therapy Does Not Alter Survival in Idiopathic Pulmonary Fibrosis
inferredcites →https://doi.org/10.1378/chest.93.1.114openalex-snapshot
Poor Prognosis in Patients with Rheumatoid Arthritis Hospitalized for Interstitial Lung Fibrosis
inferredcites →https://doi.org/10.1517/14740338.4.4.723openalex-snapshot
Methotrexate pulmonary toxicity

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4866588openalex-extracted
The Pathogenesis of Rheumatoid Arthritis Associated Interstitial Lung Disease and the Progress in the Treatment of Traditional Chinese Medicine
inferred← citeshttps://doi.org/10.1007/978-981-10-6750-1_6openalex-snapshot
Comprehensive Understanding of Interstitial Lung Disease in Rheumatoid Arthritis
inferred← citeshttps://doi.org/10.1007/978-981-10-6750-1_9openalex-snapshot
Therapeutic Strategies for Interstitial Lung Diseases in Rheumatoid Arthritis
inferred← citeshttps://doi.org/10.1007/s10067-019-04557-7openalex-snapshot
Rituximab in connective tissue disease–associated interstitial lung disease
inferred← citeshttps://doi.org/10.1007/s10067-019-04753-5openalex-snapshot
Associated factors with interstitial lung disease and health-related quality of life in Chinese patients with primary Sjögren’s syndrome
inferred← citeshttps://doi.org/10.1016/b978-0-323-48024-6.00013-6openalex-snapshot
Interstitial Lung Disease in the Connective Tissue Diseases
inferred← citeshttps://doi.org/10.1016/j.ccm.2012.01.004openalex-snapshot
Interstitial Lung Disease in the Connective Tissue Diseases
inferred← citeshttps://doi.org/10.1080/14712598.2017.1287169openalex-snapshot
Biologics-induced interstitial lung diseases in rheumatic patients: facts and controversies
inferred← citeshttps://doi.org/10.1093/rheumatology/kez673openalex-snapshot
Efficacy of rituximab in slowing down progression of rheumatoid arthritis–related interstitial lung disease: data from the NEREA Registry
inferred← citeshttps://doi.org/10.1097/cpm.0000000000000282openalex-snapshot
Immunosuppressive Treatment Regimens in Connective Tissue Disease–associated Interstitial Lung Disease
inferred← citeshttps://doi.org/10.1097/cpm.0000000000000287openalex-snapshot
Rituximab in Connective Tissue Disease–associated Interstitial Lung Disease: A Community-based Experience and Review of Literature
inferred← citeshttps://doi.org/10.1177/1759720x15612250openalex-snapshot
Treatment of rheumatoid arthritis-associated interstitial lung disease: a perspective review
inferred← citeshttps://doi.org/10.3109/14397595.2016.1173816openalex-snapshot
Efficacy of intensive immunosuppression in exacerbated rheumatoid arthritis-associated interstitial lung disease
inferred← citeshttps://doi.org/10.3389/fmed.2019.00041openalex-snapshot
Biologic Treatments in Interstitial Lung Diseases
inferred← citeshttps://doi.org/10.3390/jcm11040927openalex-snapshot
Efficacy and Safety of Rituximab in Autoimmune Disease—Associated Interstitial Lung Disease: A Prospective Cohort Study
inferred← citeshttps://doi.org/10.3390/jcm9041082openalex-snapshot
Treatment of Rheumatoid Arthritis-Associated Interstitial Lung Disease: Lights and Shadows
inferred← citeshttps://doi.org/10.3390/jcm9103070openalex-snapshot
Rituximab in the Treatment of Interstitial Lung Disease Associated with Autoimmune Diseases: Experience from a Single Referral Center and Literature Review
inferred← citeshttps://doi.org/10.4049/jimmunol.1900473openalex-snapshot
TNF-Induced Interstitial Lung Disease in a Murine Arthritis Model: Accumulation of Activated Monocytes, Conventional Dendritic Cells, and CD21+/CD23− B Cell Follicles Is Prevented with Anti-TNF Therapy
inferred← citeshttps://doi.org/10.4137/ccrpm.s23289openalex-snapshot
Up-to-Date Information on Rheumatoid Arthritis-Associated Interstitial Lung Disease
inferred← citeshttps://doi.org/10.7573/dic.2020-8-7openalex-snapshot
Efficacy and safety of rituximab in the treatment of connective tissue disease-related interstitial lung disease
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.